GLP-1 Blood Test Explained: What It Measures and Why It's Ordered

What GLP-1 Is and Where It Comes From

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted chiefly by enteroendocrine L-cells of the distal small intestine and colon in response to nutrients reaching the gut lumen. It is not synthesised as a standalone hormone: it is cleaved from a larger precursor, proglucagon, which is processed in a tissue-specific way into glucagon, GLP-1, GLP-2 and related fragments. A 2022 review in Frontiers in Nutrition examined glucagon and other proglucagon-derived peptides together and described how this shared precursor biology is relevant to the pathogenesis of obesity (PMID 35990325).

Once released, GLP-1 acts on GLP-1 receptors distributed across pancreatic islets, the gastrointestinal tract, the central nervous system and other tissues. A 2024 mechanistic review in American Journal of Physiology: Cell Physiology focused specifically on GLP-1-mediated gut-kidney cross talk in humans, arguing that GLP-1 signalling extends well beyond insulin secretion into renal and systemic physiology (PMID 38105752). That breadth is one reason GLP-1 appears as an analyte in research settings far removed from classic diabetes testing.

What a GLP-1 Blood Test Actually Measures

The phrase "GLP-1 blood test" covers several different laboratory measurements that are easy to confuse. Most are performed on plasma (frequently EDTA plasma with a DPP-4 inhibitor additive) or serum, drawn either fasting or at timed intervals during a meal or glucose challenge.

Active versus total GLP-1

The biologically active forms are GLP-1(7-36) amide and GLP-1(7-37). These are cleaved rapidly in circulation by the enzyme dipeptidyl peptidase-4 (DPP-4) into GLP-1(9-36) and GLP-1(9-37), which are no longer potent agonists at the GLP-1 receptor. An "active GLP-1" assay uses antibodies intended to capture only the intact peptide; a "total GLP-1" assay captures intact peptide plus its truncated metabolites. Because the intact hormone has a very short circulating half-life, the two results can differ by a wide margin in the same tube, and a number reported without specifying which assay was used carries limited meaning. The clinical and physiological literature on proglucagon-derived peptides treats these forms as distinct entities rather than one interchangeable "GLP-1 level" (PMID 35990325).

Hormone assays versus drug assays

A separate category of testing measures a pharmaceutical GLP-1 receptor agonist rather than the endogenous hormone. Researchers developing and characterising these molecules have relied on chromatography-based quantification: a 2023 study in Journal of Chromatography B reported a novel LC-MS/MS method for the GLP-1 analogue semaglutide and applied it to pharmacokinetic and brain distribution studies in rats (PMID 36989942). Human and nonclinical disposition work has been described in parallel; a 2017 paper in European Journal of Pharmaceutical Sciences reported on the absorption, metabolism and excretion of semaglutide in humans and nonclinical species, including metabolic breakdown of the peptide backbone and its fatty-diacid side chain (PMID 28323117). These are research and development assays, not routine hospital chemistry panels.

Why GLP-1 Measurement Is Ordered: Contexts Described in Published Work

Hypoglycaemia and hyperinsulinism

One of the better-defined clinical research contexts is unexplained low blood sugar with inappropriately high insulin. A 2022 review in Frontiers in Endocrinology examined the role of GLP-1 signalling in hypoglycaemia due to hyperinsulinism, covering both congenital hyperinsulinism and hypoglycaemia occurring after bariatric surgery, and discussed GLP-1 receptor blockade as an investigational approach in that setting (PMID 35399928). In such work, GLP-1 is usually measured dynamically during a mixed-meal or glucose challenge rather than as a single fasting number.

Obesity, appetite and gut-hormone physiology

GLP-1 is routinely measured in metabolic research as one of several proglucagon-derived peptides thought to influence satiety, gastric emptying and islet hormone secretion; the 2022 Frontiers in Nutrition review placed these peptides within models of obesity pathogenesis (PMID 35990325). Measurements in this context are typically research endpoints in a controlled protocol, not stand-alone diagnostic tests.

Renal and cardiometabolic physiology

Investigators studying how incretin signalling reaches the kidney have measured GLP-1 alongside renal handling endpoints; the 2024 review of gut-kidney cross talk in humans set out the mechanistic basis for those experiments (PMID 38105752). Related clinical pharmacology work has examined GLP-1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes, where complementary mechanisms were the stated rationale in a 2017 analysis in Diabetes, Obesity & Metabolism (PMID 28432726).

Exploratory biomarker panels

GLP-1 occasionally appears as one analyte within broad multiplex serum panels used to hunt for disease signatures. A 2025 study in Arthritis Research & Therapy investigated serum biomarkers in rheumatoid and psoriatic arthritis patients searching for disease-specific signatures, illustrating how metabolic and gut-derived analytes are screened in exploratory panels rather than ordered as targeted tests (PMID 40640860).

What the Literature Associates With High GLP-1 Values

High measured GLP-1 does not have a single meaning, and published work points to several very different explanations.

• Post-prandial and post-surgical secretion. Exaggerated nutrient-stimulated GLP-1 secretion is a recurring theme in hyperinsulinaemic hypoglycaemia research, including hypoglycaemia following bariatric surgery, as discussed in the 2022 Frontiers in Endocrinology review (PMID 35399928).
• Secretagogue exposure. Compounds that stimulate L-cells can raise secretion in experimental systems; a 2024 study in The American Journal of Chinese Medicine reported that berberine metabolites stimulated GLP-1 secretion by alleviating oxidative stress and mitochondrial dysfunction (PMID 38351702).
• Assay cross-reactivity with analogue drugs. Therapeutic GLP-1 receptor agonists are built on the native peptide sequence. The 2015 Journal of Medicinal Chemistry paper describing the discovery of the once-weekly analogue semaglutide reported structural modifications of the human GLP-1 backbone, including an albumin-binding fatty-diacid side chain, that extended its duration of action (PMID 26308095). Sequence similarity of that kind is why an immunoassay raised against endogenous GLP-1 may not cleanly separate hormone from drug, and why dedicated LC-MS/MS methods were developed for analogue quantification (PMID 36989942).

What the Literature Associates With Low or Blunted Values

Reduced or blunted nutrient-stimulated GLP-1 responses have been discussed in the context of obesity and disordered proglucagon-peptide signalling, where the 2022 review argued that the balance between glucagon, GLP-1 and related fragments — rather than any single hormone concentration — shapes metabolic phenotype (PMID 35990325). Low active GLP-1 with preserved total GLP-1 is also a recognised analytical pattern, since rapid DPP-4 cleavage converts intact peptide into fragments that a total assay still counts (PMID 38105752).

GLP-1 Receptor Agonist Literature and Safety Signals: What Studies Report

People being investigated with GLP-1 testing are sometimes also exposed to GLP-1 receptor agonists, so the published safety literature on those drugs is relevant background. A 2021 report in Biomedicines described liraglutide-induced hepatotoxicity, documenting liver injury associated with the agent (PMID 33498980). A 2025 paper in Basic & Clinical Pharmacology & Toxicology reviewed the effects of GLP-1 receptor agonists in alcohol use disorder, an area in which researchers have examined central as well as metabolic actions (PMID 39891507). Product quality is a separate issue: a 2024 study in Pharmaceutical Research reported that manufacturing process and compounding can affect the properties and quality of follow-on GLP-1 polypeptide drugs (PMID 39379664). None of this material establishes how any individual laboratory result should be read.

Assay and Interpretation Caveats

1. Pre-analytical handling dominates. Because intact GLP-1 is cleaved quickly by DPP-4, collection tube type, inhibitor additives, time on ice and processing delay can change an active GLP-1 result substantially; reviews of GLP-1 physiology emphasise the instability of the intact peptide (PMID 38105752).
2. Active and total are different analytes. Comparing a total GLP-1 value against an active GLP-1 reference interval is a category error rather than a clinical finding (PMID 35990325).
3. Timing relative to food matters. GLP-1 rises after nutrient intake, so fasting and stimulated values answer different questions; dynamic testing is the norm in hyperinsulinism research (PMID 35399928).
4. Drug exposure complicates immunoassays. Analogues derived from the native sequence may interfere with antibody-based measurement, which is why mass-spectrometric methods were developed for drug pharmacokinetics (PMID 36989942) and why disposition studies characterised analogue metabolites separately (PMID 28323117).
5. Panel results are exploratory. When GLP-1 appears inside a multiplex biomarker panel, the study design is usually signature discovery rather than individual diagnosis (PMID 40640860).

Who Interprets the Result

No reference interval is universal across GLP-1 assays, and the same specimen can generate different numbers on different platforms. Published findings describe populations and experimental conditions; they do not translate into a verdict about a single person's report. Interpretation — including whether a GLP-1 measurement was the right test, how it should be read alongside glucose, insulin, C-peptide and clinical context, and what if anything follows — belongs to the clinician who ordered it. This page is for educational purposes only and is not medical advice; consult a licensed physician about laboratory testing, test interpretation and any medical decision.

References

• Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity (Frontiers in Nutrition, 2022)
• The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight (American Journal of Physiology. Cell Physiology, 2024)
• The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism (Frontiers in Endocrinology, 2022)
• Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats (Journal of Chromatography B, 2023)
• Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species (European Journal of Pharmaceutical Sciences, 2017)
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Journal of Medicinal Chemistry, 2015)
• Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction (The American Journal of Chinese Medicine, 2024)
• Investigation of serum biomarkers in rheumatoid and psoriatic arthritis patients for disease-specific signatures (Arthritis Research & Therapy, 2025)
• Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor (Diabetes, Obesity & Metabolism, 2017)
• Liraglutide-Induced Hepatotoxicity (Biomedicines, 2021)
• Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder (Basic & Clinical Pharmacology & Toxicology, 2025)
• Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs (Pharmaceutical Research, 2024)